within Pharmacolibrary.Drugs.ATC.V;

model V03AB14
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0009333333333333333,
    adminDuration  = 600,
    adminMass      = 50 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00027,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>V03AB14</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Protamine is a cationic polypeptide used clinically to reverse the anticoagulant effects of heparin, particularly during surgeries such as cardiac and vascular procedures. It acts by binding to heparin to form a stable complex, thereby neutralizing its anticoagulant activity. Protamine is used in hospital settings and is currently approved for clinical use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for healthy adult male volunteers after intravenous administration of protamine sulfate.</p><h4>References</h4><ol><li><p>Levy, JH, et al., &amp; Iba, T (2023). What&#x27;s fishy about protamine? Clinical use, adverse reactions, and potential alternatives. <i>Journal of thrombosis and haemostasis : JTH</i> 21(7) 1714–1723. DOI:<a href=\"https://doi.org/10.1016/j.jtha.2023.04.005\">10.1016/j.jtha.2023.04.005</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/37062523/\">https://pubmed.ncbi.nlm.nih.gov/37062523</a></p></li><li><p>Butterworth, J, et al., &amp; James, R (2002). The pharmacokinetics and cardiovascular effects of a single intravenous dose of protamine in normal volunteers. <i>Anesthesia and analgesia</i> 94(3) 514–None. DOI:<a href=\"https://doi.org/10.1097/00000539-200203000-00008\">10.1097/00000539-200203000-00008</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/11867368/\">https://pubmed.ncbi.nlm.nih.gov/11867368</a></p></li><li><p>Masuda, H, et al., &amp; Hashida, M (1999). Pharmacokinetics and disposition characteristics of recombinant decorin after intravenous injection into mice. <i>Biochimica et biophysica acta</i> 1426(3) 420–428. DOI:<a href=\"https://doi.org/10.1016/s0304-4165(98)00163-9\">10.1016/s0304-4165(98)00163-9</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/10076058/\">https://pubmed.ncbi.nlm.nih.gov/10076058</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end V03AB14;
